Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls

Michala Kolarova, Urmi Sengupta, Ales Bartos, Jan Ricny, Rakez Kayed

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.

Original languageEnglish (US)
Pages (from-to)471-478
Number of pages8
JournalJournal of Alzheimer's Disease
Volume58
Issue number2
DOIs
StatePublished - 2017

Fingerprint

tau Proteins
Alzheimer Disease
Serum
Poisons
Extracellular Space
Healthy Volunteers
Pathology
Neurons
Cognitive Dysfunction
Brain
Proteins

Keywords

  • Alzheimer's disease
  • oligomers
  • serum
  • tau protein

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. / Kolarova, Michala; Sengupta, Urmi; Bartos, Ales; Ricny, Jan; Kayed, Rakez.

In: Journal of Alzheimer's Disease, Vol. 58, No. 2, 2017, p. 471-478.

Research output: Contribution to journalArticle

Kolarova, Michala ; Sengupta, Urmi ; Bartos, Ales ; Ricny, Jan ; Kayed, Rakez. / Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. In: Journal of Alzheimer's Disease. 2017 ; Vol. 58, No. 2. pp. 471-478.
@article{f3624b78657c4d4baca9291fb42eec57,
title = "Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls",
abstract = "Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.",
keywords = "Alzheimer's disease, oligomers, serum, tau protein",
author = "Michala Kolarova and Urmi Sengupta and Ales Bartos and Jan Ricny and Rakez Kayed",
year = "2017",
doi = "10.3233/JAD-170048",
language = "English (US)",
volume = "58",
pages = "471--478",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls

AU - Kolarova, Michala

AU - Sengupta, Urmi

AU - Bartos, Ales

AU - Ricny, Jan

AU - Kayed, Rakez

PY - 2017

Y1 - 2017

N2 - Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.

AB - Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.

KW - Alzheimer's disease

KW - oligomers

KW - serum

KW - tau protein

UR - http://www.scopus.com/inward/record.url?scp=85019188326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019188326&partnerID=8YFLogxK

U2 - 10.3233/JAD-170048

DO - 10.3233/JAD-170048

M3 - Article

VL - 58

SP - 471

EP - 478

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -